Forum Topic News
  • Conversation: Lexington Begins HeartSentry Clinical Trial

    • February 21, 2018 12:41 PM GMT
      • Post(s)

      Lexington Begins HeartSentry Clinical Trial

      VANCOUVER, British Columbia, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Lexington Biosciences, Inc. (CSE:LNB) (OTCQB:LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, is pleased to announce commencement of its clinical trial and first patient enrollment. These clinical studies are designed to measure the safety and effectiveness of the HeartSentry technology for cardiovascular health diagnosis.
      HeartSentry is a new non-invasive diagnostic device that is designed to measure and monitor cardiovascular health by assessing the function of a patient’s vascular endothelium, the vital innermost lining of the cardiovascular system. The core technology of HeartSentry was developed at the University of California Berkeley over a fifteen-year research and development period involving an award winning scientific team dedicated to solving the holy grail of cardiovascular medicine, being able to cost effectively predict the development and progression of cardiovascular disease. The early research studies and product iterations resulted in a portfolio of multiple pending and issued patents being licensed to the Company.
      Read more:

Add Reputation

Do you want to add reputation for this member by this post?

or cancel